Publication at First Faculty of Medicine, Third Faculty of Medicine |
2014
Abstract
Since the mid-nineties of the last century, combination antiretroviral therapy has been the main treatmentstrategy for HIV. Reverse transcriptase inhibitors are among the traditionally used drug classes.
Etravirine is a sekond-generation non-nucleoside reverse transcriptase inhibitor (NNRTI). Duet he need to combine drugs from different classes, each newly approved medicinbal product is an option for patiens with resistence or intolerance to previous therapy.
Etravirine is generally characterized by high efficacy, a low risk of side effects and a higher resistence barrier in comparison with first-generation NNRTIs.